AstraZeneca Covid Vaccine Shot Shows Promise Among Elderly I
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A potential COVID-19 vaccine developed by AstraZeneca Plc and Oxford University produced a strong immune response in older adults, giving hope it may protect some of those most vulnerable to the disease, data from mid-stage trials showed. The data suggest that those aged over 70 who are at higher risk of serious illness and death from COVID-19 could build robust immunity to the pandemic disease.

The robust antibody and T-cell responses seen in older people in our study are encouraging, said Maheshi Ramasamy, a consultant and a co-lead investigator at the Oxford Vaccine Group. The populations at greatest risk of serious COVID-19 disease include people with existing health conditions and older adults. The researchers hope that their vaccine will help to protect some of the most vulnerable people in society, but further research will be needed.

Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions. The Oxford-AstraZeneca COVID-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against infection with the novel coronavirus, or SARS-CoV-2.

But rival drugmakers Pfizer Inc, BioNTech and Moderna Inc have in the past 10 days edged ahead, releasing data from late-stage COVID-19 vaccine trials that shows more than 90% efficacy. Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA (mRNA), the AstraZeneca experimental shot is viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees.

AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world as it gets close to reporting results of its late-stage trials.

Dr. C●●●●g R●●●●●i and 1 others like this1 share